The Effectiveness of Continuous Ketamine Infusion (KONTINUE)
Prospective observational cohort (n=80) evaluating continuous intravenous ketamine infusion (0.5 mg/kg/day) plus magnesium sulfate (1000 mg/day) over 4 days for chronic pain.
Detailed Description
Prospective observational cohort (80 participants) assessing continuous IV ketamine 0.5 mg/kg/day combined with magnesium sulfate 1000 mg/day administered over four days in hospital for chronic pain.
Evaluations scheduled at day 15, 30 and 60 with outcomes focused on pain reduction and safety/tolerability assessments.
Study Protocol
Preparation
Dosing
Integration
Study Arms & Interventions
Ketamine infusion
experimentalContinuous IV ketamine 0.5 mg/kg/day for 4 days with magnesium sulfate 1000 mg/day in hospital
Interventions
- Ketamine0.5 mg/kgvia IV• continuous infusion• 4 doses total
4-day continuous infusion, 0.5 mg/kg/day
- Placebovia IV• daily• 4 doses total
Magnesium sulfate 1000 mg/day IV (co-administered)
Participants
Inclusion Criteria
- Pain lasting for more than six months without contraindication to treatment
Exclusion Criteria
- Inability to give consent
- Severe psychiatric disorder
Study Protocol, Arms & Participants
Go Pro to access detailed study protocol timelines, treatment arms, dosing schedules, and participant eligibility criteria.
Study Details
- StatusCompleted
- PhasePhase NA
- Typeobservational
- DesignNon-randomized
- Target Enrollment80 participants
- TimelineStart: 2022-02-22End: 2024-02-25
- Compounds
- Topic
Study Team
Sponsors & Collaborators
- Centre Hospitalier Princesse GracePrimary Sponsor
Locations
Your Personal Research Library
Go Pro to save trials, add notes, rate research, and organize custom shelves.